title: Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug?
abstract: OBJECTIVE
  To assess the association between obesity, control of inflammatory activity and increased adverse effects in psoriatic arthritis (PsA) with disease-modifying anti-inflammatory drugs (DMARD).
  
  
  METHODS
  A systematic literature review was performed using MEDLINE and EMBASE databases following the guidelines of the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) consensus statement. Studies were selected if they included patients with PsA, obesity was studied as a predictive factor, and the outcome was adverse effects, including efficacy failure. Quality was assessed using an ad hoc risk of bias tool. A qualitative analysis was carried out by type of study and study population, quality and specific results.
  
  
  RESULTS
  We found 1043 articles, discarding most of them on the basis of title and abstract. Ten articles were studied in detail and finally excluded three. The majority concluded, with statistically significant results, that in patients with PsA and treated with TNFα inhibitors (TNFαi), obesity is associated with poorer chances of achieving and maintaining a minimal disease activity, higher treatment discontinuation rates, and lower skin response. Regarding conventional synthetic DMARD, a trend toward a moderate increase in transaminases with methotrexate (MTX) was observed in obese patients with PsA.
  
  
  CONCLUSIONS
  Obesity is a negative predictor of clinical response in patients with PsA being treated with TNFαi. Except MTX hepatotoxicity, no other adverse effects, either with TNFαi or other drugs, were found in relation to obesity in PsA.
authors.affiliation: Servicio de Reumatología, Hospital Universitario Basurto, Bilbao, Vizcaya, España. Electronic address: evagalindez@gmail.com.
authors.forename: Eva
authors.initials: E
authors.lastname: Galíndez
authors.affiliation: Instituto de Salud Musculoesquelética, Madrid, España.
authors.forename: Loreto
authors.initials: L
authors.lastname: Carmona
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D009765:Obesity / Q000150:complications*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents
keywords: Adverse events; Artritis psoriásica; Biologics; Biológicos; Disease-modifying anti-inflammatory drugs; Efectos adversos; Fármacos modificadores de la enfermedad; Obesidad; Obesity; Psoriatic arthritis